SYN Stock Overview
Synthetica AD, through its subsidiaries, produces and sells hemodialysis and medical products in Bulgaria.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Synthetica AD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | лв55.50 |
| 52 Week High | лв55.50 |
| 52 Week Low | лв48.00 |
| Beta | 0.031 |
| 1 Month Change | 1.83% |
| 3 Month Change | n/a |
| 1 Year Change | 9.90% |
| 3 Year Change | 24.44% |
| 5 Year Change | 32.14% |
| Change since IPO | 74.64% |
Recent News & Updates
Shareholder Returns
| SYN | BG Medical Equipment | BG Market | |
|---|---|---|---|
| 7D | 0% | -0.8% | 0.9% |
| 1Y | 9.9% | 5.2% | 14.8% |
Return vs Industry: SYN exceeded the BG Medical Equipment industry which returned 5.2% over the past year.
Return vs Market: SYN underperformed the BG Market which returned 14.8% over the past year.
Price Volatility
| SYN volatility | |
|---|---|
| SYN Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.6% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in BG Market | 10.8% |
| 10% least volatile stocks in BG Market | 2.2% |
Stable Share Price: SYN has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SYN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 120 | Iva Garvanska Sofiyanska | www.synthetica.bg |
Synthetica AD, through its subsidiaries, produces and sells hemodialysis and medical products in Bulgaria. It also engages in real estate management activities; and provides solar energy, as well as heating, ventilation, air conditioning, lighting, and industrial systems. The company is based in Sofia, Bulgaria.
Synthetica AD Fundamentals Summary
| SYN fundamental statistics | |
|---|---|
| Market cap | лв166.50m |
| Earnings (TTM) | -лв1.67m |
| Revenue (TTM) | лв34.41m |
4.8x
P/S Ratio-99.9x
P/E RatioIs SYN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYN income statement (TTM) | |
|---|---|
| Revenue | лв34.41m |
| Cost of Revenue | лв28.26m |
| Gross Profit | лв6.16m |
| Other Expenses | лв7.82m |
| Earnings | -лв1.67m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.56 |
| Gross Margin | 17.89% |
| Net Profit Margin | -4.84% |
| Debt/Equity Ratio | 438.9% |
How did SYN perform over the long term?
See historical performance and comparison